These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1389 related articles for article (PubMed ID: 26376998)

  • 1. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
    Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
    Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
    Wu Y; Guo L; Liu J; Liu R; Liu M; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):1-7. PubMed ID: 24398307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect and mechanism of microRNA-21 on cis-dichlorodiamineplatinum resistance in lung cancer cell strain].
    Ren L; Huang C; Liu YH; Yu Y; Lin L; Wen LJ
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1454-8. PubMed ID: 27266356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
    Sui C; Meng F; Li Y; Jiang Y
    J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
    Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
    Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
    Yu G; Zhong N; Chen G; Huang B; Wu S
    Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.
    Ma Y; Li X; Cheng S; Wei W; Li Y
    Mol Med Rep; 2015 Jan; 11(1):625-32. PubMed ID: 25339370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
    Gong J; He L; Ma J; Zhang J; Wang L; Wang J
    J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer.
    Yu S; Qin X; Chen T; Zhou L; Xu X; Feng J
    Anticancer Drugs; 2017 Sep; 28(8):852-860. PubMed ID: 28723865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
    Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
    Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-185-5p modulates chemosensitivity of human non-small cell lung cancer to cisplatin via targeting ABCC1.
    Pei K; Zhu JJ; Wang CE; Xie QL; Guo JY
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4697-4704. PubMed ID: 27906433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
    Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
    Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS; Zheng YL; Zhao J; Chun X
    Biomed Pharmacother; 2018 Feb; 98():538-544. PubMed ID: 29287202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of shRNA on Cisplatin-resistant Non-small Cell Lung Cancer Cell A549 via Silencing
    He L; Du ZD; Wang Y; Meng RQ; Zhao WW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):312-319. PubMed ID: 32543135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
    Liu HJ; Li GL; Lei PC
    Zhonghua Zhong Liu Za Zhi; 2019 Jul; 41(7):516-521. PubMed ID: 31357838
    [No Abstract]   [Full Text] [Related]  

  • 20. [Reversion of multidrug resistance of human gastric cancer SGC7901/DDP cells by E2F-1 gene silencing].
    Lian C; Yang J; Wang X; Xie Y; Xiao Q
    Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):171-6. PubMed ID: 24785275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 70.